Levonorgestrel (LNG), a dedicated emergency contraception (EC) product, has been available over-the-counter in China for more than 14 yr. Although LNG-EC is considered to have no effects on the developing fetus if the contraceptive fails and pregnancy occurs, there have been a few studies specifically examining this issue. The purpose of this study was to compare the physical and mental development of children born after LNG-EC failure with that of a cohort of children born to mothers with no history of exposure to LNG or any teratogenic substances. A group of 195 children who were exposed to LNG-EC during their mothers' conception cycle (study group) were matched to a group of 214 children without exposure to LNG (control group). The physical and mental development of the children were evaluated and compared over a 2-yr period. There were four congenital malformations in the study group and three in the control group (2.1% vs.
INTRODUCTION
Levonorgestrel (LNG) administered at a dose of 1.5 mg (given as either a single 1.5-mg dose or two 0.75-mg doses taken 12 h apart) is a safe and well-tolerated method for emergency contraception (EC), and today it is the gold standard for oral EC [1] [2] [3] . The mechanisms of LNG-EC action have not been fully characterized, but the main mechanism is considered a delay or inhibition of ovulation [4] . However, the window of effect for LNG-EC seems to be rather narrow, beginning after selection of the dominant follicle and ending when the luteinizing hormone (LH) peak begins to rise, and LNG appears not to have a direct inhibitory effect on follicular rupture, which allows it to also be effective even when administered shortly before ovulation [5, 6] . Recent in vitro human embryo implantation studies have shown that LNG does not interfere with postfertilization events [7] .
Although LNG-EC is considered to have no effects on the developing fetus if the contraceptive fails and pregnancy occurs [2, [8] [9] [10] [11] [12] [13] [14] , there have been a few studies specifically examining this issue. Some animal studies have indicated a dose-dependent virilization of female fetuses related to LNG's androgenic characteristics [15, 16] , and human studies have indicated that progestins can exert masculinizing effects on female fetuses, but exposure during the eighth to 10th weeks of gestation and high doses are required [8] . To our knowledge, only one retrospective observational cohort study has specifically examined the effects of LNG-EC on the fetus in cases of contraceptive failure. De Santis et al. [17] found no differences in neonatal outcomes between 36 women who were exposed to LNG and 80 control women.
LNG-EC has been sold over the counter for more than 14 yr in China, and it is estimated that the market increased from 0.5 million in 1998 to 50 million in 2005 [18] . The increased use of LNG-EC has raised concerns regarding the results of EC failure. The currently reported pregnancy (failure) rate with LNG-EC is 0.2%-3.0% [1] . Because most people purchase the pills directly from pharmacies, without seeing a physician in China [19] , the LNG-EC user failure is high [20, 21] , and the absolute number of EC failures is higher compared to that in other countries [22] . When LNG-EC fails, some women in China want to continue their pregnancies but hesitate because of concerns of drugrelated fetal abnormalities [22] .
In 2009, we reported pregnancy outcomes of 332 women who were exposed to LNG in early pregnancy, and compared to 332 unexposed women, there were no statistically significant differences in the miscarriage rate, delivery pattern, gestational age, rate and type of birth defects, and sex ratio between the two groups [21] . However, drug effects on offspring sometimes occurred later. Since 2005, we have followed this patient cohort to explore the possible late consequences of LNG-EC exposure in the children. Thus, the purpose of this study was to compare the physical and mental development of children born after LNG-EC failure with that of a cohort born to mothers with no history of exposure to LNG or any teratogenic substances.
MATERIALS AND METHODS
The initial study was performed from November 1999 to August 2008 in Shanghai, and selection criteria and results were reported previously [21] . Briefly, a group of 332 pregnant women who had used LNG-EC during the conception cycle was matched to a group of 332 normal pregnant women not exposed to EC. The control group was randomly selected from healthy pregnant women attending the same outpatient clinic during the same period of time who had not taken any teratogenic drugs during the 3 mo prior to their last menstrual period (LMP). The women in the study and control groups were matched for LMP and maternal date of birth (DOB). Every time a LNGexposed woman was enrolled, an investigator selected a pregnant patient with the nearest DOB and LMP from the patients seen at the outpatient clinic on the previous week. Selecting subjects by DOB and LMP dates allowed matching the two groups' ages at the beginning of pregnancy and probable gestational ages at enrollment in the study. Patients with chronic disease or known organ dysfunction, mental illness, or fertility disorders or who had been exposed to a known teratogen since their LMP were excluded from the study.
A group of 238 pregnant women consecutively presenting for counseling after LNG-EC failure was matched to a group of 238 normal pregnant women not exposed to EC, between July 2004 and August 2008 in Shanghai. This study included patients whose neonates were born from 2005 to 2009 and finished the follow-up after delivery. A flow diagram of subject enrollment is shown in Figure 1 .
The primary outcome measures were physical and mental development. Secondary outcome measures included congenital defects and severe diseases 
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in the two groups. Physical examinations included measurements of the children's weight, height, and head circumference. The Developmental Screening Test (DST) for children under six was used to evaluate the children's mental and motion ability development [23] . The DST is based on Chinese children's mental development characteristics and pediatric care in China and was developed by Shanghai Medical University Pediatric Hospital in collaboration with six hospitals around the country in an effort to develop national standards [23, 24] . The DST is a 120-item questionnaire that contains categories of motor development, social adaption, and intelligence and was developed based on several accomplishment standards including the Denver Developmental Screening Test (DDST), the Gesell development standards, and the Wechsler Preschool and Primary Scale of Intelligence (WPPSI). The DST has been validated in children 0-6 yr of age [23, 25] and has been shown to have the same sensitivity and specificity as the DDST [23, 26] . The quantitative results of the DST were expressed as development quotient (DQ) and mental index (MI), which were transformed from raw scores by deviation (see formulas listed below). A score of !85 indicates normal development, 70-84 means suspicious, and ,70 indicates mental development delay. DQ ¼ total scores of 120-item questionnaires, derived by 100 þ (X DQ À Y DQ ) / S DQ 3 15; MI ¼ subtotal scores of ''intelligence'' category, derived by 100 þ (X MI À Y MI ) / S MI 3 15; S ¼ standard deviation, pre-defined as ¼ 15; X ¼ mean scores of subjects; Y ¼ standard mean scores of the corresponding age category of subjects, predefined as Y ¼ 100.
Physical and mental examinations were administered at 3, 6, 12, and 24 mo of age. The children's weight, height, and head circumference measurements were collected from hospital records or by a telephone call to patients who lived outside Shanghai. DQ and MI measurements were determined by specialists in the pediatric outpatient department. During the process of observation, the follow-up conditions were similar in both groups. Before recruitment, patients received complete information about the effects of LNG-EC on themselves and their babies and were provided with written informed consent. Ethics approval for the survey was obtained from the local hospital research ethics committee.
Data Analysis
Continuous data were presented as means 6 SD, and categorical data were expressed as numbers and percentages. Differences in characteristics between the two groups (study group vs. control group and LNG .1.5-mg vs. LNG 1.5-mg groups) were detected by independent t-test for continuous data and by chi-square test or Fisher exact test for categorical data, as appropriate. Relative risk (RR) and 95% confidence intervals (CIs) were calculated for the incidence rate of malformations between the study and control groups.
For repeatedly measured data of infant (followed at 3, 6, and 12 mo) and toddler (followed at 24 mo) outcomes (weight, height, head circumference, DQ, and MI), a generalized linear model with generalized estimating equations (GEE) was applied to investigate the effect of groups regarding LNG use (denoted as group effect), follow-up time after birth (denoted as time effect), and their interaction (denoted as group 3 time). The group effects on infant and toddler outcomes were investigated in two categories: (a) two-group comparisons of study group versus control group; and (b) three-group comparisons of high-dose LNG (.1.5 mg), low-dose LNG ( 1.5 mg), and control group.
All statistical analyses were performed with SAS software version 9.2 (SAS Institute Inc., Cary, NC). A two-tailed P value of ,0.05 indicated statistical significance.
RESULTS
A total of 402 women were included in the study, with 191 mothers in the study group (LNG-EC exposure) and 211 in the control group (Fig. 1) . Among the 191 subjects in study group, 172 (90.1%) took LNG-EC at a dose of 1.5 mg, and 19 (9.9%) took a dose of .1.5 mg. The day when LNG-EC was taken (first course) varied from Day 2 to Day 44 of menstrual cycles (Fig. 2) . Comparisons of maternal characteristics between subjects exposed to LNG-EC and the control group are shown in Table 1 . The LNG-EC-exposed mothers had a greater number of previous pregnancies than those in the control group (P ¼ 0.001). Body weight before pregnancy was significantly lower in the study group than in the control group (52.5 6 5.9 kg vs. 54.1 6 7.3 kg, respectively, P ¼ 0.011). There were no significant differences in maternal age, paternal age, place of residence, education level, occupation, maternal height, weight before delivery, or type of delivery between the two groups (Table 1) . Comparisons between the high-dose (.1.5-mg) and low-dose ( 1.5-mg) LNG-EC-exposed mothers did not show significant differences (Table 1) .
A total of 409 neonates were born from the 402 subjects. Among them, 195 neonates were born from mothers with LNG-EC exposure, and 214 were unexposed to LNG-EC. No significant differences were found in the distribution of type of delivery, gestational age, preterm delivery, post-term delivery, birth weight, birth height, and sex ratio between two groups at birth (Table 2) . Comparisons between neonates from the highdose (.1.5-mg) and low-dose ( 1.5-mg) LNG-EC-exposed mothers did not show significant differences (Table 2) .
Four neonates in the study group and three in the control group had congenital defects ( Table 3) . None of the women whose children had congenital defects had a family history of genetic diseases. Of note, there was one case of intussusception in each group. The incidence of congenital malformations was INFANT DEVELOPMENT AFTER LEVONORGESTREL EC slightly higher in the study group than in the control group (2.05% vs. 1.40%, respectively), but the differences were not statistically significant (RR ¼ 1.46, 95% CI: 0.33-6.46; P ¼ 0.713). There was one second trimester abortion in the control group that was considered to be due to a congenital malformation [21] . That case was not included in the analysis, as the primary outcome measures of the study were the physical and mental development for those born alive. However, further statistical analysis including that case still resulted in no statistical difference in the incidence of congenital malformations between the study and control group (2.05% vs. 1.86%, respectively; RR ¼ 1.10, 95% CI ¼ 0.28-4.35; P ¼ 0.889).
The youngest child was 2 yr old, and the oldest was 7 yr old at the end of the study. Within the first 2 yr after birth, 25 infants or toddlers were lost to follow-up: 14 in the study group and 11 in the control group. The physical development measured within the first 2 yr (infants at 3, 6, and 12 mo and toddlers at 24 mo) is shown in Figure 3 . According to GEE analysis, no significant effect of LNG-EC was found on weight ( Fig. 3a , P ¼ 0.124), height ( Fig. 3b, P ¼ 0.139) , and head circumference ( Fig. 3c , P ¼ 0.711) within the first 2 yr after birth. Similarly, weight (Fig. 3d , P ¼ 0.061), height ( Fig. 3e , P ¼ 0.350), and head circumference (Fig. 3f , P ¼ 0.308) in the high-and low-dose LNG-EC exposure groups were not significantly different from those of the control group. After further adjustment for the potential confounders of physical development (maternal age, education, place of residence, paternal age, pregnancy complications, type of delivery, birth weight, and gestational age at birth), no differences in weight, height, and head circumference of the infants or toddlers in the LNG-EC-exposed and -nonexposed groups were noted (all, P . 0.05).
Approximately 50% of the mothers in the study were residents of Shanghai, and the others were from distant suburbs or different provinces. For this reason, only 30%-40% of the parents brought their children to the hospital for the mental development examinations on time. The DQ and MI scores of 3 . Physical development of infants measured at 3, 6, and 12 mo and of toddlers at 24 mo. Weight (a), height (b), and head circumference (c) of the study group were compared to those of the control group; and weight (d), height (e), and head circumference (f) were compared among the high-dose (.1.5-mg), low-dose ( 1.5-mg), and control groups. Data are means 6 SD. The number of infants followed at 3, 6, and 12 mo and toddlers at 24 mo were 195, 192, 184, and 181, respectively for the study group (19 were followed at all time points for the high dose group), and 214, 213, 206, and 203 for the control group. Error bars for each group are located at the 3-, 6-, 12-, and 24-mo time points. A slight separation between error bars among groups at the same time point was made to avoid overlapping.
INFANT DEVELOPMENT AFTER LEVONORGESTREL EC measurements made within the first 2 yr after birth are shown in Figure 4 . According to GEE analysis, no significant effect of LNG-EC was found on DQ ( Fig. 4a , P ¼ 0.591) or MI scores ( Fig. 4b , P ¼ 0.896) within the first 2 yr after birth. Furthermore, DQ ( Fig. 4c , P ¼ 0.476) and MI scores ( Fig.  4d , P ¼ 0.862) of infants or toddlers in the high-and low-dose LNG-EC exposure groups were not significantly different from that of the control group. After further adjustment for potential confounders of DQ and MI scores (maternal age, education, place of residence, paternal age, pregnancy complications, type of delivery, birth weight, and gestational age at birth), no differences in DQ and MI scores between LNG-EC-exposed and nonexposed groups were noted (all, P . 0.05).
DISCUSSION
Our study shows for the first time in a large series of pregnancies that LNG-EC taken during the cycle of conception, even at relatively high doses (.1.5 mg and up to 9 mg in one cycle), appears to have no significant consequences on an offspring's physical and mental development and incidence of congenital malformations. Most studies of LNG-EC are concerned with conception efficiency and side effects and include only limited data regarding the outcome of the infants. LNG-EC is considered to have no effects on the developing fetus, if the contraceptive fails and pregnancy occurs [1, [8] [9] [10] [11] [12] [13] [14] , and the only retrospective cohort study specifically examining the effects of LNG-EC on the fetus in cases of contraceptive failure found no differences in neonatal outcomes between 36 women who were exposed to LNG and 80 control women [17] . In China, however, many gynecologists have doubts about the safety of EC in the event of a subsequent pregnancy. Furthermore, many women who experience LNG-EC failure are concerned about the impact of EC on the fetus and, due to China's one-child policy, choose to terminate the pregnancy.
LNG administered at a dose of 1.5 mg is a safe and welltolerated method for EC. When taken within 72 h after intercourse, this method prevents 75%-85% of pregnancies that would occur without treatment [2, 3, 22] . The mechanism of action of LNG-EC is not fully understood. If administered at least 2 days prior to the LH surge, LNG causes either a delay or an inhibition of the LH surge and therefore delays or inhibits ovulation [6, 27] . It has been demonstrated that LNG-EC acts through an effect on follicular development to delay or inhibit ovulation but has no effect once LH has started to increase [6, 27] . Thereafter, LNG-EC cannot prevent ovulation, and it does not prevent fertilization or affect the human fallopian tube. LNG-EC has no effect on endometrial development or function. In an in vitro model, it was demonstrated that LNG did not interfere with blastocyst function or implantation [28] . LNG-EC does not prevent embryo implantation, and therefore cannot be considered an abortifacient [29] .
It is generally thought that any drug exposure before conception or during the following 2 wk will not have an adverse effect on the embryo. Although in vitro studies have shown that LNG does not interfere with postfertilization events, dose-dependent effects should be noticed. While there have been reports of female virilization following progestogen exposure [15, 16] , there were no cases of virilization or urinary tract anomalies among the 96 female newborns in the study group within the first 2 yr of life.
There were no differences in weight, height, and head circumference between the LNG-EC-exposed infants and the unexposed infants within the first 2 yr of life. The average growth measurements of the two groups were in accordance with the physical development of children under 7 yr of age in Shanghai in 2005 [30] . Numerous factors can affect the growth and development of children: genetics, sex, endocrine effects, maternal conditions, disease, nutrition, and living environment [31] [32] [33] . Although maternal weight before pregnancy and the number of pregnancies were different between the exposed and unexposed groups, the birth weight, height, and physical growth of the infants were not different.
Neurological developmental outcomes according to the DST in the LNG-EC exposed group were not different than those of infants in the control group. Because family environment and education may influence intellectual development [26, 33] , we chose to perform behavioral and intellectual screening in children from 3 mo to 2 yr of age in order to focus on the effects of drug exposure and to minimize the effects of environment and education. In our study, rates of abnormal DQ scores (,70) in the study group at 3 and 6 mo were 4.4% and 2.9%, respectively, and 3.4% and 3.0%, respectively, in the control group at 6 and 12 mo. The rate of abnormal MI score (,70) in the study group at 3 mo was 2.9%. Compared with the national rates of abnormal DQ and MI scores of 2.5% and 2.7%, respectively, the rates in this study were slightly higher than the national standards [23, 25] . This finding is perhaps because of the relatively small sample size or because the parents of children with low DQ scores were more willing to test their children. Nevertheless, the differences in scores between the two groups were not statistically significant. Interestingly, a recent study found that advancing paternal age is associated with increased risk of autism, attention-deficit/ hyperactivity disorder, psychosis, bipolar disorder, suicide attempts, substance use problems, and failing grades in offspring [34] . As the paternal age of the two groups in this study was similar, any effect of age should be similar between the groups. , and 12 mo and of toddlers at 24 mo, respectively. DQ (a) and MI (b) were compared between the study group and control group; DQ (c) and MI (d) were further compared among high-dose (.1.5 mg) and low-dose ( 1.5 mg) levonorgestrel and control groups. Data are means 6 SD. The number of infants followed at 3, 6, and 12 mo and of toddlers at 24 mo were 68, 68, 57, and 61 in the study group (9, 9, 7, and 8 in the high-dose group), and 68, 59, 67, and 63 in the control group, respectively. Error bars of each group are located at 3-, 6-, 12-, and 24-mo time points. A slight separation between error bars among groups at the same time point was made to avoid overlapping.
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It should be noted that most pharmacies in China deliver EC pills without specific information regarding the proper indications and usage [35] . This lack of information makes most LNG-EC failures ''user failure'' [22] , and this accounted for more than 70% of failures in this study. The most common cause was repeated unprotected intercourse in one menstrual cycle, and in some cases women used LNG-EC more than once during one conceptive cycle. LNG was taken between day 3 and 69 of the conception cycle, and the cumulative dose of LNG taken varied from 0.75 to 9 mg depending on the number of treatments used during the conception cycle [21] .
There are a number of limitations to this study that should be considered. The number of women who were exposed to a dose of LNG at .1.5 mg was relatively small (19 of 195) . One case of a second trimester abortion because of an identified congenital malformation was not included in the study; however, inclusion of the case did not change the results regarding the incidence of malformations between the two groups. Feeding and nutrition (such as breastfeeding and supplements) are important factors that affect an infant's growth; however, this study focused on the effects of LNG-EC, and we did not evaluate the impact of nutritional factors on infants. Last, the number of infants and toddlers that completed the developmental follow-up was relatively low, and thus, the analysis of the differences between groups is underpowered.
The results of this observational study of more than 400 subjects indicated that LNG-EC has no effect on the physical growth or mental development or the occurrence of birth defects in infants born from pregnancies in which EC failed. The use of LNG-EC should not be a primary reason for pregnancy termination after LNG-EC failure.
